327 related articles for article (PubMed ID: 28844598)
1. Exceptional Response to Nivolumab Rechallenge in Metastatic Renal Cell Carcinoma with Parallel Changes in Genomic Profile.
Dizman N; Bergerot P; Bergerot C; Lanman RB; Raymond VM; Banks KC; Jones J; Pal SK
Eur Urol; 2018 Feb; 73(2):308-310. PubMed ID: 28844598
[No Abstract] [Full Text] [Related]
2. Case of complete response to neoadjuvant therapy using nivolumab in a patient with metastatic renal cell carcinoma.
Ikarashi D; Kato Y; Katagiri H; Takahara T; Uesugi N; Shiomi E; Sugimura J; Nitta H; Sugai T; Obara W
Int J Urol; 2018 Jun; 25(6):630-632. PubMed ID: 29693280
[TBL] [Abstract][Full Text] [Related]
3. NICE Guidance - Nivolumab for previously treated advanced renal cell carcinoma: © NICE (2017) Nivolumab for previously treated advanced renal cell carcinoma.
BJU Int; 2018 Sep; 122(3):362-370. PubMed ID: 30187657
[No Abstract] [Full Text] [Related]
4. Efficacy and Toxicity of Fifth-line Nivolumab in a 15-Year-Old Girl With Metastatic Juvenile Renal Cell Carcinoma.
Akbaraly T; Saguintaah M; Topart D; Sirvent N
J Pediatr Hematol Oncol; 2018 Apr; 40(3):251-252. PubMed ID: 29420369
[No Abstract] [Full Text] [Related]
5. C-reactive protein can be used to predict the therapeutic effects of nivolumab in patients with metastatic renal cell carcinoma.
Teishima J; Murata D; Hasegawa Y; Moriyama H; Mita K; Matsubara A
Int J Urol; 2019 Nov; 26(11):1076-1077. PubMed ID: 31368187
[No Abstract] [Full Text] [Related]
6. Complete Response of a Patient With Metastatic Sarcomatoid Renal Cell Carcinoma to a Programmed Death-1 Checkpoint Inhibitor.
El Mouallem N; Smith SC; Paul AK
J Oncol Pract; 2018 Aug; 14(8):511-513. PubMed ID: 29920137
[No Abstract] [Full Text] [Related]
7. Newly developing brain metastases during nivolumab therapy for metastatic renal cell carcinoma: A case series in two Japanese institutions.
Ishihara H; Kondo T; Takagi T; Yoshida K; Okumi M; Tanabe K
Int J Urol; 2019 Aug; 26(8):849-850. PubMed ID: 31115103
[No Abstract] [Full Text] [Related]
8. Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy.
Vitale MG; Scagliarini S; Galli L; Pignata S; Lo Re G; Berruti A; Defferrari C; Spada M; Masini C; Santini D; Ciuffreda L; Ruggeri EM; Bengala C; Livi L; Fagnani D; Bonetti A; Giustini L; Hamzaj A; Procopio G; Caserta C; Sabbatini R
PLoS One; 2018; 13(7):e0199642. PubMed ID: 29979712
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of risk stratification using blood parameters for nivolumab in Japanese patients with metastatic renal-cell carcinoma.
Yamamoto Y; Matsuyama H; Matsumoto H; Sakano S; Fuji N; Oba K; Yamamoto M; Kamiryo Y; Hiragino T; Nagao K; Takai K; Aoki A
Jpn J Clin Oncol; 2020 Feb; 50(2):214-220. PubMed ID: 31755525
[TBL] [Abstract][Full Text] [Related]
10. An evaluation of nivolumab for the treatment of metastatic renal cell carcinoma.
Zarrabi K; Wu S
Expert Opin Biol Ther; 2018 Jun; 18(6):695-705. PubMed ID: 29782188
[TBL] [Abstract][Full Text] [Related]
11. Pseudoprogression: A case of metastatic renal clear cell carcinoma treated with nivolumab.
Tabei T; Tsuura Y; Kobayashi K
Pathol Int; 2018 Nov; 68(11):627-629. PubMed ID: 30151940
[No Abstract] [Full Text] [Related]
12. [First-line therapy in advanced renal cell carcinoma : A randomized phase II study to examine early switch of tyrosine kinase inhibitors to nivolumab compared to continued tyrosine kinase inhibitor therapy in patients with advanced or metastatic renal cell carcinoma and stable disease after three months of treatment (NIVOSWITCH)-AN 38/15 of the AUO].
Rexer H; Steiner T; Grünwald V
Urologe A; 2017 Apr; 56(4):509-511. PubMed ID: 28251253
[No Abstract] [Full Text] [Related]
13. [A Case of Nivolumab-Induced Isolated Adrenocorticotropic Hormone Deficiency Presenting Dyspnea].
Ito K; Uchida T; Manabe Y; Miyazaki Y; Itoh H; Mishina M; Okuno H
Hinyokika Kiyo; 2018 Oct; 64(10):391-395. PubMed ID: 30543736
[TBL] [Abstract][Full Text] [Related]
14. Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab.
Zahoor H; Barata PC; Jia X; Martin A; Allman KD; Wood LS; Gilligan TD; Grivas P; Ornstein MC; Garcia JA; Rini BI
J Immunother Cancer; 2018 Oct; 6(1):107. PubMed ID: 30333065
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety profile of nivolumab for Japanese patients with metastatic renal cell cancer.
Fujiwara R; Inamura K; Yuasa T; Numao N; Yamamoto S; Masuda H; Kawauchi A; Takeuchi K; Yonese J
Int J Clin Oncol; 2020 Jan; 25(1):151-157. PubMed ID: 31522314
[TBL] [Abstract][Full Text] [Related]
16. Safety of nivolumab in metastatic renal cell carcinoma patients: A real-life experience in a Spanish urology setting.
Amores Bermúdez J; Osman García I; Unda Urzáiz M; Jiménez Marrero P; Ledo Cepero MJ; Llarena R; Flores Martín J; Abad Vivas-Pérez JI; Rodrigo Aliaga M; Juarez Soto A
Actas Urol Esp (Engl Ed); 2019 Sep; 43(7):364-370. PubMed ID: 31097211
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment of metastatic clear cell carcinoma with nivolumab in a patient receiving dialysis treatment.
Tabei T; Natsume I; Kobayashi K
Int J Urol; 2017 Sep; 24(9):708-710. PubMed ID: 28734029
[TBL] [Abstract][Full Text] [Related]
18. [Nivolumab combined with ipilimumab versus sunitinib monotherapy-SUNNIFORECAST AN 41/16 of the AUO : A phase 2, randomized, open-label study in subjects with previously untreated and advanced (unresectable or metastatic) non-clear cell renal cell carcinoma].
Rexer H; Steiner T; Bergmann L
Urologe A; 2017 Jun; 56(6):802-803. PubMed ID: 28536740
[No Abstract] [Full Text] [Related]
19. Second-line cabozantinib versus nivolumab in advanced renal cell carcinoma: Systematic review and indirect treatment comparison.
Porta C; Szczylik C; Casciano R; Fu S; Amzal B; Lister J; Karcher H; Meng J; Neumann M; Dinet J
Crit Rev Oncol Hematol; 2019 Jul; 139():143-148. PubMed ID: 30401604
[TBL] [Abstract][Full Text] [Related]
20. [A Case of Rheumatoid Arthritis Developed during Treatment with Nivolumab for Renal Cell Carcinoma].
Tomizawa M; Nakai Y; Maesaka F; Owari T; Hara R; Miyake M; Inoue T; Anai S; Tanaka N; Fujimoto K
Hinyokika Kiyo; 2018 Oct; 64(10):397-401. PubMed ID: 30543737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
